Low-level
elevations in important markers of systemic inflammation are associated with
the development of type-2 diabetes in people taking antiretroviral therapy
(ART), investigators report in the online edition of the Journal of Acquired Immune Deficiency Syndromes. The authors
examined the relationship between baseline levels of high sensitivity
C-reactive protein (hsCRP) and interleukin-6 (IL-6) and incident
Targeted adherence measures and viral load monitoring needed to improve retention in South African ART programme
57%
of people living with HIV in South Africa who are eligible to initiate antiretroviral
therapy (ART) are in care and only 37% of the 2012/2013 cohort of people
receiving ART were given a viral load test, according to new results announced
by the CEO of the South African National AIDS Council (SANAC) at
Stribild: un nuovo regime a single tablet regimen disponibile
«Siamo passati dal niente, al complicato, al semplice». Con queste poche ma chiare parole, Rosaria Iardino, presidente onorario di Network Persone Sieropositive (NPS) Italia Onlus, sintetizza l’evoluzione della terapia anti Hiv in 30 anni, da quando il virus fu scoperto e identificato.
HIV treatment roll-out has had only a modest impact on mortality in Lusaka, Zambia
The scale-up of
antiretroviral therapy (ART) programmes in Lusaka, Zambia, has been
accompanied by only modest reductions in the city’s mortality rates,
investigators report in the Bulletin of
the World Health Organization. A series of cross-sectional household
surveys conducted between 2004 and 2011 showed no significant reduction in the
mortality rate. The authors admit this finding
HIV-related stigma has increased in Uganda despite treatment roll-out
HIV continues to
be stigmatised despite increased access to antiretroviral therapy (ART),
according to research from Uganda published in the online edition of AIDS. Levels of internalised stigma
among people starting ART increased between 2007 and 2012. There was also an
increase in the proportion of individuals in the general public who said they
expected
The treatment cascade in the United States – good in Ryan White programmes, but overall picture for gay men is poor
People living with HIV in the United States who receive
their care through the Ryan White HIV/AIDS Program have good rates of retention
and virological suppression, investigators report in the online edition of Clinical
Infectious Diseases. Of the patients seen at least once in 2011, some 82%
were retained in care and 73% achieved virological
People with hepatitis B who have cirrhosis should be prioritised for liver cancer screening
Liver cancer
screening for people with hepatitis B virus (HBV) infection should be
targeted at those with cirrhosis, according to the results of a systematic
review and meta-analysis published in PLOS
ONE. The risk of hepatocellular carcinoma (HCC) and death were 31- and 44-
times higher, respectively, in people with liver cirrhosis compared to people
PrEP will need high adherence, high effectiveness and high coverage in specific populations to be affordable in the US, New York study finds
A
study based on New York City that modelled pre-exposure prophylaxis (PrEP) uptake there has found that in
order to be affordable, PrEP would need to be tightly
targeted at gay men at higher risk of HIV infection. Within this target
population, it would need high levels of usage.
A
reduction in the price of Truvada
Sovaldi sarà rimborsabile: trovato accordo Aifa-Gilead
Sarà rimborsabile il Sovaldi, il nuovo e costosissimo farmaco per l‘Epatite C. L’Agenzia Italiana del Farmaco ha trovato l’accordo con la casa farmaceutica che lo produce, la Gilead Sciences. Il prezzo del Sofosbuvir (così si chiama il principio attivo), già calato da 58 mila a 37 mila euro per ciclo terapeutico, aveva scatenato le proteste delle associazioni dei malati.
Nearly half of HIV-positive gay men could benefit from being vaccinated against HPV, say Irish researchers
A study of gay men in Ireland that has investigated the prevalence of infection
with human papillomavirus (HPV), some types of which cause genital warts
and cervical, anal and oral cancers, concludes that 47% of HIV-positive and 64%
of HIV-negative gay men would benefit from being given one of the HPV vaccines against
the